Category: Covid-19

  • Industry Accused of Profiting from Ban

    Industry Accused of Profiting from Ban

    Photo: Tobacco Reporter archive

    Tobacco companies have profited handsomely from South Africa’s ban on tobacco sales imposed by the government in response to the Covid-19 pandemic, according to a prominent academic.

    “The behavior of the tobacco industry during the lockdown has been nothing short of disgraceful … the fact is that tobacco companies have been actively selling in the illicit market,” said Corne van Walbeek, director of the Research Unit on the Economics of Excisable Products at the University of Cape Town.
     
    He said 90 percent of cigarettes sold since March 27, when the ban took effect, were of brands produced locally, giving the lie to the claim by industry groups that the black market was flooded with counterfeit products.
     
    The government in May allowed cigarette companies to resume export production, and trade experts have said this gave them cover to circumvent the sales ban by exporting excess volumes that were then smuggled into the South African black market.
     
    Van Walbeek said the Fair-Trade Independent Tobacco Association (Fita), the first tobacco group to challenge the ban in court, had increased its market share to around 60 percent during the 140-day-old ban.
     
    “The fact that Fita instituted the court case is especially ironic in that their members have been the main beneficiaries of the sales ban,” said Van Walbeek. “Fita members have greatly increased their market share and have increased the price of their product by nearly 500 percent on average.”
     

  • Lawmakers Urge Ban on E-Cigs During Pandemic

    Lawmakers Urge Ban on E-Cigs During Pandemic

    Photo: Tobacco Reporter archive

    Lawmakers have called on the U.S. Food and Drug Administration (FDA) to take e-cigarettes temporarily off the market during the pandemic, citing a new study suggesting that vapers are significantly more likely to contract Covid-19.
     

    Raja Krishnamoorthi

    “If we reduce the number of vapers in America, we will reduce the unnecessary stress we are putting on our testing system,” Representative Raja Krishnamoorthi wrote in a letter sent to the FDA by the House Committee on Oversight and Reform’s Subcommittee on Economic and Consumer Policy. “People should not have to wait weeks for Covid-19 test results—removing the risk posed by vaping will help.”
     
    Researchers at the Stanford University School of Medicine found that among young people who were tested for the coronavirus, those who vaped were five times to seven times more likely to be infected than those who did not use e-cigarettes.
     
    The study, which was published online Aug. 11 in the Journal of Adolescent Health, is the first to examine connections between youth vaping and Covid-19 using U.S. population-based data collected during the pandemic.
     
    “Young people may believe their age protects them from contracting the virus or that they will not experience symptoms of Covid-19, but the data show this isn’t true among those who vape,” said the study’s lead author, Shivani Mathur Gaiha.
     
    “This study tells us pretty clearly that youth who are using vapes or are dual-using are at elevated risk, and it’s not just a small increase in risk; it’s a big one,” Gaiha said.
     
    Remarkably, the researchers did not find a connection between Covid-19 diagnosis and smoking conventional cigarettes alone, perhaps because the prevalent pattern among youth is to use both vapor devices and traditional cigarettes. Other research has shown that nearly all nicotine-using youth vape, and some also smoke cigarettes, but very few use cigarettes only.
     
    In addition to warning teenagers and young adults about the dangers of vaping, the researchers said they hoped their findings will prompt the FDA to further tighten regulations governing how vapor products are sold to young people.
     
    “Now is the time,” said senior author Halpern-Felsher. “We need the FDA to hurry up and regulate these products. And we need to tell everyone: If you are a vaper, you are putting yourself at risk for Covid-19 and other lung disease.”
     

    John Dunne, director of the UKVIA
    John Dunne

    Vaping advocates expressed concern about the study.
     
    “While we welcome any research which can assist people in staying safe during the Covid-19 pandemic, the UKVIA [U.K. Vaping Industry Association] is disappointed by the Stanford-led study, which appears to dismiss the vital harm reduction role of vaping for smokers and draws disproportionate conclusions,” said John Dunne, director at the UKVIA.
     
    Insisting there is no scientific evidence linking smoking and vaping with Covid-19, Dunne said the UKVIA was looking forward to seeing the peer review of the Stanford study.
     
    “It is also somewhat reckless in stating that vapers are putting themselves ‘at risk of Covid-19’ by vaping,” he said. “Vaping products are designed only for smokers and ex-smokers to help them quit conventional cigarettes, which is the most positive action someone can take to improve their health.”

  • Zimbabwe: Output Expected to Stay Firm

    Zimbabwe: Output Expected to Stay Firm

    A Zimbabwean farm worker loads leaf onto a truck
    Photo: Taco Tuinstra

    The Zimbabwean tobacco industry expects leaf production to hold up despite the Covid-19-related restrictions on movement and a ban on cigarette sales in neighboring South Africa, reports The Herald.

    “I don’t foresee any marked change, which would lead to a reduction in the production of tobacco in Zimbabwe,” Paul Zakariya, director of the Zimbabwe Farmers Union, was quoted as saying.

    “Covid-19 is just one among other major factors that may affect production,” he added, pointing to other challenges such as the rising cost of inputs.

    Tobacco farmers and tobacco auctions were exempted from Zimbabwe’s lockdown and curfew regulations. To limit large gatherings of people, smaller deliveries of leaf were combined into larger ones for transport to the sales floors. And instead of attending the sales process in person, groups of farmers sent representatives. (Also see our June 2020 feature story “Silent Auction”).

    The global tobacco market will reach $66,42 billion (in retail prices), increasing at an average of 2.6 percent a year between 2019 to 2024, according to a recent report published by Research and Markets.  

    Despite a drought in the 2018-2019 cropping season, Zimbabwe still managed to produce a record-breaking tobacco output, reaching an all-time high of 258 million kg.

    In the current marketing season, farmers have so far sold 159 million kilograms of tobacco worth $390 million as trading reaches its peak under the World Health Organization Covid-19 health guidelines.

    The Tobacco Industry and Marketing Board expects farmers to produce about 224 million kg of tobacco are expected this season, down from the previous year’s output level of 259.5 million kilograms owing largely to drought.

  • BAT Vaccine May Start Clinical Trials Soon

    BAT Vaccine May Start Clinical Trials Soon

    Tobacco companies have joined the race to develop a vaccine against Covid-19
    Image: Gerd Altmann from Pixabay

    British American Tobacco’s (BAT) experimental Covid-19 vaccine may start clinical trials within weeks, reports Bloomberg, citing BAT Chief Marketing Officer Kingsley Wheaton.

    The maker of Lucky Strike cigarettes said it expects a response from U.S. Food and Drug Administration (FDA) any day now.

    Kingsley Wheaton

    “We’re optimistic,” Wheaton said. “It’s an important part of our strategy to try and build a better tomorrow.”

    In April BAT announced it was developing a Covid-19 vaccine from tobacco leaves and could produce 1 million to 3 million doses per week if it got the support of government agencies and the right manufacturers.

    Earlier this year, BAT submitted a pre-investigative new drug application to the FDA. It is also talking with other government agencies about the vaccine.

    Multiple companies from a variety of sectors have been racing to develop a vaccine for Covid-19, with some of the vaccines already in human trials. Experts have suggested that a Covid-19 vaccine could take 12-18 months to develop.

    BAT said it has committed funds to conduct clinical trials. The company has reportedly also invested in additional equipment to boost capacity. The company’s investment in a Covid-19 vaccine were covered in-depth in Tobacco Reporter’s June issue.

    Medicago, a biotechnology company partly owned by Philip Morris International, is also developing a plant-based vaccine that could be available in the first half of 2021.

    There are 24 vaccine candidates in clinical trials, though nine out of 10 such programs typically fail during trials, according to the World Health Organization.

  • Honduras Orders Cigar Factories to Close

    Honduras Orders Cigar Factories to Close

    Photo courtesy of Sebastian Zimmel

    The Honduran government has ordered the closure of cigar factories as the number of Covid-19 cases in the area spikes.
     
    The city of Danli and the district of El Paraiso will return to phase zero as of Wednesday, July 22. This means only pharmacies, supermarkets and gas stations will remain open.
     
    The closure will reportedly last for at least 15 days.
     
    This will be the second government-mandated closure this year. The first came after Covid-19 began to hit the area—only six cases were confirmed at the time. The number of confirmed cases has now reached over 30,000, including the Honduran president. There have been 835 deaths as of Friday.

  • Medicago Starts Human Trials of Covid Vaccine

    Medicago Starts Human Trials of Covid Vaccine

    Photo: Dimitri Houtteman from Pixabay

    Medicago, a Quebec-based biotechnology company backed by Philip Morris International as well as other large investors, has begun human testing for its Covid-19 vaccine, reports Bloomberg.

    The vaccine is derived from the plant nicotiana benthamiana, a close relative to tobacco, to provoke an immune response to the virus.

    Medicago’s human trials will involve 180 patients ages 18 to 55. It will test various doses of the vaccine, both alone and combined with two adjuvants—one from GlaxoSmithKline and another from Dynavax Technologies.

    If the trial is successful, Medicago plans to start late-stage trials in October and manufacture 100 million doses by the end of next year.

  • Trump Officially Withdraws From WHO

    Trump Officially Withdraws From WHO

    It’s official. The Trump administration has withdrawn the United States from the World Health Organization. The news comes as the Covid-19 pandemic continues to grip the globe and infections spike across the U.S.

    Withdraw requires a years notice, so it will not go into effect until July 6, 2021. This raises the possibility the action could be overturned. 

    Congress received formal notification of the decision on Tuesday, more than a month after President Donald Trump announced his intention to end the U.S. relationship with the WHO and blasted the multilateral institution as a tool of China, according to an article in USA Today.

    Democrats said the decision was irresponsible and ill-considered, noting it comes as the pandemic is raging and international cooperation is vital to confront the crisis.

    “This won’t protect American lives or interests – it leaves Americans sick & America alone,” Sen. Bob Menendez, the top Democrat on the Senate Foreign Affairs Committee, tweeted after receiving the White House’s notification. “To call Trump’s response to Covid chaotic & incoherent doesn’t do it justice.”

    The formal withdrawal comes as the United States nears 3 million reported coronavirus cases and more than 130,000 deaths, according to Johns Hopkins University data. Globally, there have been 11.6 million cases and almost 540,000 deaths, according to the story.

    Trump and his advisers have blasted the WHO for failing to press China to be more transparent about the scope and severity of the Covid-19 outbreak, which began in Wuhan, China.

    Trump has said that China “has total control” over the WHO, even though it contributes far less than the US to the health organization’s budget. The U.S. has contributed approximately $450 million dollars a year, according to the story.

    Amanda Glassman, a public health expert and executive vice president of the Center for Global Development think tank, noted the world doesn’t just face today’s threat of Covid-19 but also the threat of future pandemics, which are more likely because of increased zoonotic transmission.

  • Rethinking Business

    Rethinking Business

    Photo: Tobacco Reporter archive

    The impact of the Covid-19 pandemic may endure after the crisis.

    By George Gay

    The Covid-19 pandemic has created a lot of problems for the leaf tobacco trade, problems that have ranged from irritations to major hurdles, but it has been reasonably even-handed with them. While one business might have been in a better position than another to deal with these problems because of, say, its contacts or the strength of its business model, all businesses have had to face similar problems.

    This was brought home to me by a comment made by Rainer Busch of NewCo when he opined that nobody really knew how to do business in the current circumstances. In an email answer to a question about predicting future unmanufactured tobacco trade, he responded with a question of his own: Who knows what comes next? The additional level of doubt caused by the pandemic, he said, was an obstacle for everyone trying to forecast requirements and sales. Every company, he suggested, would be concerned about the future.

    Advertisement

    Busch’s main problems so far have had to do with logistics. Movements within Europe had been difficult because travel restrictions and infection warnings had limited the availability of trucks, he said, a problem that had been exacerbated by closed border crossings. This had meant that, for a while, transport prices had risen significantly, though now [Busch’s email was dated May 22], with lockdowns easing, the situation was changing, and transport companies were having to compete for orders.

    Looking at the wider picture, shipping problems had been caused initially by a lack of containers, which were bunkered in large quantities in China, and even now, some ports are still functioning only to a limited extent. At the same time, not being allowed to travel had changed tobacco business culture, said Busch, though he intimated that the industry was nothing if not innovative and flexible. Although it was usually necessary to visit the countries of origin to gain a full picture of crop quality and market conditions, business was still being conducted. Investments had been made in internet communications, and home office work had been introduced.

    Initially, shipping problems were driven by a lack of containers, which were bunkered in large quantities in China. (Photo: Transcom Sharaf)

    Protecting stakeholders

    All companies that responded to TR’s request for information have relied on switching to remote working and conferencing, and it is alarming to consider what might have happened if the pandemic had struck in pre-internet days. Premium said in a June 1 email message that its primary response to the pandemic had been focused on protecting its employees and their families by conforming to or surpassing the requirements of the countries in which it operates. But, at the same time, it had been at pains to reassess the way it operated so as to find innovative ways of protecting its business interests, in part by replacing the traditionally crucial personal contacts with remote working and conferencing systems. For the time being, all nonessential business travel had been suspended while the company monitored the situation.

    Protecting the interests of its staff and customers, however, has not been easy. Grant Readings said that at times it had been difficult to deal with regulations that differed from country to country, though he added that Premium had managed so far to keep its companies operating at a reasonable capacity by having its management teams stay vigilant and fully engaged with the authorities and other industry stakeholders in the countries in which they operated.

    Advertisement

    Interestingly, Readings said the pandemic had not severely disrupted communications between the company’s agronomists and growers and that the company had interacted with the authorities and relevant stakeholders in Brazil, Malawi, Tanzania, Uganda and Zimbabwe to ensure that buying operations were secure and efficient while remaining transparent. Premium’s Brazil factory had been running at capacity, and the company was expecting that all processing in Argentina, Malawi, Tanzania, Uganda and Zimbabwe would continue with relatively little disruption. Keeping other facilities open and functioning was described as an ongoing challenge but one the company was determined to meet.

    Most people have been affected by travel restrictions, and Readings said Premium’s customers had been unable to visit the various countries of origin to inspect tobacco as they normally would. For this reason, some disruption in ordering patterns was expected, and, potentially, the shifting of some product inspections to destination ports. At the same time, the reduction in available shipping routes and in the frequency of services on some of the available routes had led to longer-than-usual delays in shipping, but Premium indicated it was working with customers to minimize such delays.  

    Teleworking presents a challenge for a business that relies heavily on personal contacts and product inspections. (Photo: Taco Tuinstra)

    Beyond the mitigation plans

    Overall, and given the way that people’s lives have been hugely and negatively affected by the pandemic, the outlook for the leaf tobacco trade is generally optimistic. Readings said there had been no major slowdown in demand for leaf tobacco, and he wrote of a possible future increase in demand for flue-cured, stable demand for air-cured burley and increased interest in better-value dark fire-cured and oriental. Premium, he added, believed business could start to normalize in the next three months to five months [August–October].

    In part, this optimism springs from the supply side since the major production countries of South America and Africa are still operational. On the demand side, Readings said, it was assumed that some of the bigger manufacturers were reviewing their requirements in light of whatever impact the pandemic was having on consumption while regional and smaller manufacturers were expected to increase their buying activities from about July as is traditionally the case.

    Meanwhile, in a May 21 email comment that seemed to echo Busch’s remark about the difficulty in knowing what to do in the present circumstances, HN Ramprasad, chief executive of ITC Leaf Tobacco Business, made the point that while the Covid-19 pandemic struck quickly, giving businesses little time to respond, it also set challenges not covered by existing risk and mitigation plans.

    Nevertheless, he said, ITC’s deep links with the farming community and its presence across the supply chain meant that it was able to act swiftly in supporting growers in crop production thereby ensuring the continuity of its operations all the while adhering to the Indian government’s health and safety directives.

    When the government announced a lockdown on March 24, India’s internationally oriented leaf tobacco industry faced two different challenges. Flue-cured tobacco growers in Karnataka were preparing for their planting season while those in Andhra Pradesh had almost finished curing their tobacco and were getting ready for auction sales.

    In Karnataka, ITC’s local field staff helped ensure there were adequate supplies of quality seeds and the village nursery areas needed to grow them, and it supported growers in respect of best practices in nursery management while in Andhra Pradesh, field staff concentrated on advising growers about the best way to store tobacco on their farms so as to maintain its color and quality.

    Overall, ITC, which many years ago was in the vanguard of using computers to assist growers, leveraged its technology, including an ITC app, a dedicated WhatsApp group and one-to-one phone calls along with village-based field staff, to encourage best farming and safety practices. In addition, during the lockdown, ITC’s partnership project that sets up water plants in rural villages became even more important because, as well as providing a continuous supply of clean drinking water to more than 175,000 people, it meant that growers and workers didn’t have to travel outside their villages to fetch water for household purposes. To date, 140 water purification plants have been established to serve 200 villages.

    ITC said that tobacco auctions had resumed after a 40-day lockdown in phases and amid heightened safety precautions, which meant that the pace of the auctions was slower than would normally be the case. However, the company’s warehouses and processing facilities were little affected once the necessary permissions were obtained to operate them with appropriate safety measures, which included the thermal scanning of workers, the wearing of face masks, the use of hand washing and sanitizers, and implementing social distancing rules. In fact, Ramprasad said that ITC’s processing factory had started as early as the first week of April, almost within a week after lockdown, demonstrating agility and resilience.”

    Interstate movements of vehicles and port operations presented major challenges during the initial days of the lockdown in India. (Photo: Taco Tuinstra)

    Constraints

    Local transport also caused little problem given the implementation of official safety procedures, but interstate movements of vehicles and port operations presented major challenges during the initial days of the lockdown as vehicles were stopped by police at check posts. But the situation eased following appropriate representations, and ITC reported that, on the supply side, all activities were returning to normal at a much faster pace than had been expected.

    On the other hand, said Ramprasad, the situation at end markets might take more time to return to normalcy. There were still operational issues at some destination ports, from increased restriction and documentation requirements to complete lockdowns. The reduced trading across the globe had resulted also in a reduction in the availability of containers and the number and frequency of ships. 

    Otherwise, from an export viewpoint, Ramprasad said the constraints had affected travel, the dispatch of samples and the acceptance of grade standards by customers. The auction market delays had meant that samples could not be sent on time to allow customers to confirm orders for the new crop, which could lead to a reduction in demand for 2020 India crop tobaccos, though the extent of such a reduction was difficult to estimate at the time.

    Ramprasad said he expected the industry to experience a short-term slowdown due to the impact of the Covid-19 pandemic, but he said he was “hopeful of regaining full demand for Indian tobacco in [the] long run due to its versatility and ability to deliver consistent supply of superior sustainable product at competitive prices.”

    There is no doubt, however, about the short-term damage that has been caused. Maddi Venkateswara Rao, director of the India-based, unmanufactured tobacco supplier, Maddi Lakshmaiah & Co. (ML Group), made the point that the pandemic’s effects would mean that every business would be negatively affected up to the end of this year and perhaps beyond and that tobacco was not going to be exempted.

    In a May 25 email, Rao said the ML Group was still assessing the situation and that it was too early to conclude whether the aftermath of the pandemic would bring a downturn or upturn in demand for leaf tobacco. Much would depend upon the cultivation and consumption policies of the largest tobacco producer, China. But he added that, following the pandemic, there was a possibility that global cigarette sales would be affected and the ML Group, a supplier to the global market, was concerned about how this might turn out.

    As of mid-May, major leaf producing countries, such as Tanzania, were still operational (Photo: Taco Tuinstra)

    Lasting impact

    But that is for the future. Leaf businesses have suffered substantially already. Rao described how during India’s lockdown, the ML Group’s tobacco operations had come to a standstill—from purchasing to processing and shipping. Although some relaxations of India’s lockdown, originally set to last until the last day of May, were allowed from about May 10, in general, it was not possible to meet growers or others involved in the tobacco business, and no auctions were held.

    Processing of leaf had been interrupted, which meant keeping unprocessed stocks in the company’s warehouses, something that would impact costs and therefore sales. It had been impossible to keep facilities open because it was not possible to guarantee the safety of workers, who were advised to stay at home during the lockdown and to take all precautionary measures by following government guidelines. By virtue of their nature, said Rao, tobacco operations could not be done sitting at home online.

    Travelling had been seriously disrupted by the lockdown, said Rao, and there had been no new movements of cargo either by road or ship. The ML Group had faced difficulty in supplying customers with documents relating to tobacco already in transit, and it had had further difficulty in obtaining documentation, such as phytosanitary certificates. Subsequently, financial inflows and outflows were disrupted.

    But perhaps there is light at the end of the tunnel. Shortly before Rao responded to TR’s questions, lockdown relaxations had seen the resumption of about 30 percent of public transport and the ML Group was able to resume processing operations on a limited scale, adhering to government guidelines in respect of physical distancing and by providing personal protective equipment, including masks and sanitizers.

    Finally, looking to the future, Busch, whose comments opened this piece, thinks that the experience of the pandemic will have a permanent, or at least long-term, impact on the future of the leaf business, with fewer trips being made and more work from home being allowed. “Fortunately, we have our representatives and partners in most origins and are therefore always up to date on information about crop qualities, market developments and availabilities,” he said. “I miss being able to visit the origins to do my own crop evaluation, but the team does an excellent job of keeping me up to date.”

    While in retrospect the pandemic will of course be seen in a highly negative light, perhaps some good will be gleaned from it. Perhaps in being forced to reassess how it does business, the leaf industry, for instance, will identify areas where its operations could be improved. Certainly, any reduction in air travel would be a welcome boon for the environment, which is a woefully underestimated pandemic.

  • Their Favorite Enemy

    Their Favorite Enemy

    The coronavirus crisis has reinforced anti-tobacco activists’ existing worldviews.

    By Stefanie Rossel

    The coronavirus pandemic could have been a chance for public health authorities and governments to promote tobacco harm reduction (THR). Instead, they resorted to well-known, tried-yet-unproven remedies, restricting sales channels or banning tobacco products altogether.

    To warn against smoking, an activity linked to respiratory problems, appears to be a no-brainer when a deadly virus with the potential to cause acute lung failure is spreading rapidly around the globe. Yet many governments and public health authorities went much further. The Covid-19 outbreak amplified tobacco control policies that had been in circulation for decades, creating an opportunity to implement measures that would otherwise be unthinkable.

    Based on the assumption, not scientific evidence, that people who smoke or vape may be at greater risk for Covid-19, anti-tobacco campaigners considered the pandemic the perfect opportunity to suggest that smokers and vapers quit both habits, preferably through willpower but otherwise with the aid of nicotine-replacement therapy (NRT).

    In times of pressure, well-researched subjects, such as nicotine addiction, the differentiation between tobacco and nicotine and the method of nicotine delivery, appear to play an even smaller role than usual. How else to explain the decision of many jurisdictions to close vape shops during the first weeks of the pandemic? Even the U.K., a bastion of enlightenment in terms of tobacco harm reduction, ranked vape shops as “nonessential businesses.” As recently as 2019, Public Health England had reaffirmed its recommendation of vaping, which it considers to be 95 percent less harmful than smoking, as a cessation tool.

    Advertisement

    Critics warned the closure of U.K. vape shops would drive vapers back to cigarettes—a worry borne from a study carried out in May by The Guardian. The survey found that about 2.2 million people are smoking more than usual while 4.8 million are smoking the same amount and 1.9 million have decreased the amount they smoke. The rise in smoking has been attributed to heightened stress and anxiety related to the lockdowns. Smoking is also used as an excuse to go outside. The freedoms that come with working from home, without the restrictions that apply in the workplace, have also aided in the rise, the study’s authors said.

    South Africa went furthest by banning tobacco and vapor product sales altogether. Imposed to slow the spread of the coronavirus, the prohibition had serious unintended consequences. The country’s illicit cigarette trade, which, according to Bloomberg, already cost the government ZAR7 billion ($401 million) a year in lost tax revenue before the prohibition, exploded following the ban.

    A survey of 16,000 people conducted by the University of Cape Town found that 90 percent of smokers who wanted to buy cigarettes during the lockdown were able to do so, albeit at inflated prices. Not only did the ban turn thousands of consumers into lawbreakers, it also forced people to travel and interact with dealers who had potentially touched numerous other people while selling their wares. At the time of writing, the tobacco ban remained in place even as the government had started easing other restrictions, such as that on selling alcohol.

    Advertisement

    Critics warned the closure of U.K. vape shops would drive vapers back to cigarettes—a worry borne from a study carried out in May by The Guardian. The survey found that about 2.2 million people are smoking more than usual while 4.8 million are smoking the same amount and 1.9 million have decreased the amount they smoke. The rise in smoking has been attributed to heightened stress and anxiety related to the lockdowns. Smoking is also used as an excuse to go outside. The freedoms that come with working from home, without the restrictions that apply in the workplace, have also aided in the rise, the study’s authors said.

    South Africa went furthest by banning tobacco and vapor product sales altogether. Imposed to slow the spread of the coronavirus, the prohibition had serious unintended consequences. The country’s illicit cigarette trade, which, according to Bloomberg, already cost the government ZAR7 billion ($401 million) a year in lost tax revenue before the prohibition, exploded following the ban.

    A survey of 16,000 people conducted by the University of Cape Town found that 90 percent of smokers who wanted to buy cigarettes during the lockdown were able to do so, albeit at inflated prices. Not only did the ban turn thousands of consumers into lawbreakers, it also forced people to travel and interact with dealers who had potentially touched numerous other people while selling their wares. At the time of writing, the tobacco ban remained in place even as the government had started easing other restrictions, such as that on selling alcohol.

    When Kentucky BioProcessing announced a breakthrough in developing a tobacco-based Covid-19 vaccine candidate, the WHO was quick to warn governments against engaging with the tobacco industry.
    (Photo: Kentucky Bioprocessing)

    Spreading misinformation

    The South African government based its tobacco ban on advice from the World Health Organization (WHO), which maintains that although research is still being carried out, there is reason to believe that smokers would be more adversely affected than nonsmokers if they contracted Covid-19. Similar claims were made by authorities in other jurisdictions. Vaping, for example, was singled out as a risk factor for Covid-19 by New York City’s mayor, Bill de Blasio, the U.S. surgeon general and the U.S. National Institute on Drug Abuse. Even the U.S. Food and Drug Administration lumped vaping with smoking in the coronavirus context—but backtracked quickly in the absence of proof.

    “Such misinformation ultimately harms the credibility of such bodies,” says David Sweanor, chair of the Advisory Board for the Center for Health Law, Policy and Ethics at the University of Ottawa. “Due to the role of the internet in compiling information and social media for sharing it, deception is no longer a viable strategy. It was never an ethical one. These bodies have been engaging in credibility self-immolation at a time when credibility and trust in government health bodies is essential to their role in countering Covid-19.”

    Advertisement

    While there are plenty of studies on the subject now, research into the relationship between tobacco use and Covid-19 remains inconclusive. Early in the pandemic, however, two meta-analyses found that smoking was not a risk factor for Covid-19 hospitalization. On the contrary, one of the researchers, Konstantinos Farsalinos, a cardiologist at the university of Patras, Greece, suggested that nicotine might even reduce the risk of contracting the coronavirus.

    When examining Chinese data on Covid-19 patients, Farsalinos observed an unusually low prevalence of current smoking among Covid-19 patients compared to the expected prevalence based on smoking rates in China. While about one third of Chinese adults smoke, only 9.6 percent of hospitalized Covid-19 patients were smokers. Studies in the U.S., France and Germany noticed similar discrepancies between the share of smokers among hospitalized Covid-19 patients and their share in the general population.

    The protective effect, Farsalinos speculated, could be linked to the downregulation of angiotensin-converting enzyme 2 (ACE2) expression. The coronavirus is known to use the ACE2 for cell entry. In a peer-reviewed paper published in Toxicology Reports, Farsalinos also suggested that by maintaining or restoring the cholinergic anti-inflammatory system, nicotine could control the release of pro-inflammatory cytokines and thus prevent or suppress a “cytokine storm.” Cytokines are proteins that help organize the body’s immune response to infections. A cytokine storm, often found in patients with a severe form of Covid-19, represents a failure of the inflammatory response to return to normal operation, which can potentially lead to catastrophic tissue damage.

    Jean-Pierre Changeux, professor emeritus of molecular neurobiology at College de France and Institut Pasteur, went a step further. To test the protective properties of nicotine, he initiated a human trial in May. It involved groups of healthcare workers and patients wearing nicotine patches and other groups wearing placebo patches. According to Reuters, similar testing will be carried out on 400 hospitalized Covid-19 patients to understand if nicotine alters the progress of the disease. While the scientists emphasized that their research wasn’t meant to encourage smoking, French authorities limited sales of NRTs to avoid a shortage.

    Konstantinos Farsalinos (Photo: David Parker)

    Harmful approach

    The idea that nicotine may have benign properties, that the much-demonized tobacco plant might contribute something positive, fits poorly with anti-tobacco campaigners’ worldviews. When British American Tobacco announced in April that its subsidiary Kentucky BioProcessing had made a breakthrough in developing a tobacco plant-based vaccine candidate for Covid-19 (see “Shots on Goal,” Tobacco Reporter, June 2020), the WHO was quick to warn governments against engaging with the tobacco industry. Partnership with the tobacco industry, the global health body stated, undermines governments’ credibility in protecting population health as there is “a fundamental and irreconcilable conflict between the tobacco industry’s interests and public health policy interests.”

    The WHO’s May 11 statement on tobacco use and Covid-19 may be read in a similar way—as a preemptive discreditation of all studies that might not be in line with the organization’s ideology. “WHO stresses the importance of ethically approved, high-quality, systematic research that will contribute to advancing individual and public health, emphasizing that promotion of unproven interventions could have a negative effect on health.”

    The organization has been criticized for its handling of the coronavirus crisis. It has been accused of acting too slow to halt the pandemic and of opaqueness under influence from China. “The WHO is not helping public health,” said Tim Andrews, founder and president of the Australian Taxpayers’ Alliance, in a webinar held by the Reason Foundation. “Just think of its failures in the Covid-19 crisis.”

    The WHO has a track record of preventing reduced-risk products (RRPs), an approach that has killed millions of people, according to Andrews. The WHO, he says, has strayed from its original aims, a development that became visible when it initiated the Framework Convention on Tobacco Control in 2003. “As the policies of the WHO failed, people at the same time adopted RRPs, thus smoking rates declined,” said Andrews. “The WHO had two choices: either accept e-cigarettes or double down on their measures. They opted for the latter.”

    The more e-cigarettes and heated-tobacco products prove to be effective harm reduction tools, the more the WHO regulates against them, according to Andrews. “If people are scared of RRPs, they will stick to combustible cigarettes,” he cautioned. “The WHO has been deliberately lying and spreading misinformation.”

    How the misunderstanding of nicotine will impact THR in the long run remains to be seen. Sweanor remains confident. “I am optimistic that Covid-19 will lead to a reexamination of public health bodies and public health policies in general,” he says. Many of the failings with nicotine, such as acting on unscientific authoritarian impulses rather than focusing on pragmatically reducing risks for the most vulnerable, have been tragically repeated with Covid-19, according to Sweanor. “If basic public health principles and ethics could be reestablished in major health bodies such as the WHO and CDC [the U.S. Centers for Disease Control and Prevention], it could lead to breakthroughs not just on pandemic responses and nicotine but on a wide range of other pressing issues.”

  • Challenge to Cigarette Ban Dismissed

    Challenge to Cigarette Ban Dismissed

    South Africa’s ban on tobacco sales has caused the black market for cigarettes to explode, according to industry sources (Photo: BAT)

    The Pretoria High Court has dismissed a bid by the Fair Trade Independent Tobacco Association (Fita) to lift South Africa’s ban on cigarette sales during the country’s coronavirus lockdown.

    South Africa banned the sale of tobacco in March and extended the measure even as it lifted its ban on alcohol sales on June 1.

    In announcing the High Court ruling, Judge President Dunstan Mlambo referenced the country’s state of disaster.

    He said disasters, by their nature, may result in unforeseen consequences, but governments have to implement measures to manage and contain them.

    The court also rejected Fita’s argument that cigarettes ought to have been considered essential because they are addictive.

    “The fact that a substance is addictive does not render it essential,” it stated. “We therefore find no basis on which to interpret the level 5 regulations as permitting the sale of tobacco products.”

    Fita will reportedly appeal the judgment.

    A separate challenge to the tobacco ban, brought by local market leader British American Tobacco (BAT), is scheduled to be heard in August.

    Unlike the case mounted by Fita, BAT challenges the constitutionality of the ban.

    In an affidavit, BAT South Africa executive Andre Joubert argues the government failed to make a convincing legal argument that the ban was legally necessary or to provide legitimate arguments to show smoking increased the chance of contracting Covid-19, or that smokers would be worse off than nonsmokers if they contracted the virus.

    Citing the rapidly rising illegal trade in cigarettes, BAT is pleading to have the case heard earlier than August.